These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33010459)

  • 1. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma.
    Albiges L; Barthélémy P; Gross-Goupil M; Negrier S; Needle MN; Escudier B
    Ann Oncol; 2021 Jan; 32(1):97-102. PubMed ID: 33010459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
    Choueiri TK; Albiges L; Barthélémy P; Iacovelli R; Emambux S; Molina-Cerrillo J; Garmezy B; Barata P; Basu A; Bourlon MT; Moon H; Ratta R; McKay RR; Chehrazi-Raffle A; Hammers H; Heng DYC; Braendle E; Beckermann KE; McGregor BA; Motzer RJ
    Lancet; 2024 Oct; 404(10460):1309-1320. PubMed ID: 39284329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
    Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
    J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
    Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF
    Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of tivozanib in advanced renal cell carcinoma therapy.
    Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
    Molina AM; Hutson TE; Nosov D; Tomczak P; Lipatov O; Sternberg CN; Motzer R; Eisen T
    Eur J Cancer; 2018 May; 94():87-94. PubMed ID: 29547835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
    Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
    Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
    Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
    Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
    Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
    Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
    Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
    Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tivozanib for the treatment of advanced renal cell carcinoma.
    Chatzkel J; Ramnaraign B; Sonpavde G
    Expert Opin Pharmacother; 2022 Jul; 23(10):1135-1142. PubMed ID: 35848061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
    Cowey CL
    Drug Des Devel Ther; 2013; 7():519-27. PubMed ID: 23818763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
    Niwakawa M; Yamaguchi R; Onozawa Y; Yasui H; Taku K; Naito T; Akinaga S; Boku N; Yamamoto N
    Cancer Sci; 2013 Aug; 104(8):1039-44. PubMed ID: 23679664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
    Benson AB; Kiss I; Bridgewater J; Eskens FA; Sasse C; Vossen S; Chen J; Van Sant C; Ball HA; Keating A; Krivoshik A
    Clin Cancer Res; 2016 Oct; 22(20):5058-5067. PubMed ID: 27401244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.
    Agulnik M; Costa RLB; Milhem M; Rademaker AW; Prunder BC; Daniels D; Rhodes BT; Humphreys C; Abbinanti S; Nye L; Cehic R; Polish A; Vintilescu C; McFarland T; Skubitz K; Robinson S; Okuno S; Van Tine BA
    Ann Oncol; 2017 Jan; 28(1):121-127. PubMed ID: 27771610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
    Kang SK; Volodarskiy A; Ohmann EL; Balar AV; Bangalore S
    Clin Oncol (R Coll Radiol); 2016 May; 28(5):334-41. PubMed ID: 26723100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.
    Mayer EL; Scheulen ME; Beckman J; Richly H; Duarte A; Cotreau MM; Strahs AL; Agarwal S; Steelman L; Winer EP; Dickler MN
    Breast Cancer Res Treat; 2013 Jul; 140(2):331-9. PubMed ID: 23868188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
    Viray H; McDermott DF; Einstein DJ
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):695-702. PubMed ID: 35698870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
    Mehta A; Sonpavde G; Escudier B
    Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tivozanib: a new treatment option for renal cell carcinoma.
    Saes L; Eskens FALM
    Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.